Advanced Therapies Week 2022 | Innovations in viral vector development

Nathalie Clement, PhD, Unicorn Consultations, Gainesville, FL, discusses strategies for safe and effective viral vector development. Whilst there are a variety of viral vectors including adeno-associated viral (AAV) vectors, there are common safety concerns. However, collaboration between stakeholders can drive innovation, especially in the case of developing an AAV-based COVID-19 vaccine, which required quick adaptation of existing technology for vaccine manufacturing. Dr Clement additionally describes research to improve vector yields as well as efforts to discover more efficient capsids. This interview took place at Advanced Therapies Week 2022.